Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06545331 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06545331 · ClinicalTrials.gov record · last posted 2026-06-22

Study of XB010 in Subjects With Solid Tumors

StatusRecruiting
PhasePhase 1
SponsorExelixis
Started2024-08-06
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Amendment record 12 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 12 times since 2024-08-07; most recent amendment 2026-06-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06545331
Lead Sponsor Exelixis
Conditions Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Enrollment 396 participants
Start Date 2024-08-06
Primary Completion 2026-11-23 (estimated)
Study Completion 2027-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-22